全部 标题 作者 关键词 摘要
DOI: 10.3971/j.issn.1000-8578.2015.03.015
Keywords: A Meta-analysis,UGCG is Involved in Oxaliplatin Resistance Mechanism of Human Colon Cancer Through Regulating MDR1/P-gp Expression,Chemotherapy Promotes Mesenchymal Stem Cells Homing by Enhancing Cytokine Receptors Expression on Tumor Cells,Clinical Investigation on Qingfei Mixture Combined with Chemotherapy on Middle and Advanced Non-small Cell Lung Cancer,Predictive Factors for Customizing Chemotherapy on Advanced Lung Adenocarcinoma,Differences of Clinical Features and Short-term Efficacy Between Diffuse Large B-cell Lymphomas of HIV-infected and Non-HIV-infected Patients,Efficacy and Safety of Weekly Liposome-paclitaxel or Oxaliplatin Combined with Tegafur on Elderly Advanced Gastric Cancer,Risk Factors Associated with Hematologic Toxicity in Concurrent Chemoradiotherapy and IMRT for Cervical Cancer,Clinical Investigation on Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy on Patients with Peritoneal Carcinomatosis from Epithelial Ovarian Cancer
Full-Text Cite this paper Add to My Lib
摘要 目的 探究含奥沙利铂方案与FOLFIRI方案对Ⅳ期结直肠癌化疗疗效及预后影响的差别与K-ras基因状态的关系。方法 收集2010年1月至2012年1月的118例接受含奥沙利铂方案或FOLFIRI方案化疗的Ⅳ期结直肠癌患者临床资料，统计患者的治疗有效率（ORR）、疾病控制率（DCR）、无进展生存时间（PFS）和总生存期（OS）。采用χ2检验比较各组临床因素差别和两种治疗方案的有效率及疾病控制率，采用Kaplan-Meier法比较无进展生存时间以及总生存期。结果 118例患者中，接受含奥沙利铂方案化疗的K-ras突变型患者PFS及OS较接受FOLFIRI方案化疗患者延长（P=0.048；P=0.037），ORR及DCR较接受FOLFIRI方案化疗患者无明显差别（P=0.961；P=0.931）。接受含奥沙利铂方案化疗的K-ras野生型患者ORR、DCR、PFS及OS较接受FOLFIRI方案化疗患者无明显差别（P=0.900；P=0.802；P=0.738；P=0.904）。结论 采用含奥沙利铂方案一线化疗较FOLFIRI方案对K-ras突变型Ⅳ期结直肠癌患者更有优势，而对于K-ras野生型Ⅳ期结直肠癌患者，含奥沙利铂方案与FOLFIRI方案疗效及预后情况相当
Full-Text
Contact Us
service@oalib.com
QQ:3279437679
WhatsApp +8615387084133
